Working... Menu

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00383396
Recruitment Status : Completed
First Posted : October 3, 2006
Last Update Posted : February 13, 2007
Information provided by:
Innovative Medical

Brief Summary:
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Condition or disease Intervention/treatment Phase
Pterygia Drug: Topical Cyclosporine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All

Inclusion Criteria:

  • pts with symptomatic pterygia unresponsive to palliative treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00383396

Layout table for location information
United States, Florida
Dr. Schechter
Boynton Beach, Florida, United States, 33426
Sponsors and Collaborators
Innovative Medical
Layout table for investigator information
Principal Investigator: Barry Schechter, MD Florida Eye Microsurgical Institute

Layout table for additonal information Identifier: NCT00383396     History of Changes
Other Study ID Numbers: 1963
First Posted: October 3, 2006    Key Record Dates
Last Update Posted: February 13, 2007
Last Verified: February 2007

Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctival Diseases
Eye Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors